Base Composition for Tape Agent
Abstract
The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.
Claims
exact text as granted — not AI-modified1 . A composition for a non-aqueous patch preparation comprising a drug, an organic solvent, and a powder which is insoluble both in the organic solvent and in a lipophilic plaster base material, wherein the powder for an adhesive layer is contained as shown in the following inequality:
0.2×(the weight of the adhesive layer)×(the bulk density of the powder)≤the amount of the powder to be added≤0.6×(the weight of the adhesive layer)×(the tap density of the powder).
2 . The composition according to claim 1 , wherein the powder is at least one selected from the group consisting of crystalline cellulose, anhydrous silicic acid, starch, carmellose, carmellose metal salt, kaolin, agar, carrageenan, pectin, and powdered sugar.
3 . The composition according to claim 1 or 2 , wherein the powder is a mixture of powders.
4 . The composition according to any one of claims 1 to 3 , wherein the organic solvent comprises a fatty acid-based ionic liquid and/or a salicylic acid-based ionic liquid.
5 . The composition according to claim 4 , wherein the fatty acid-based ionic liquid is an equimolar salt of a saturated or unsaturated fatty acid having 3 to 22 carbon atoms and an alkanolamine having 6 to 9 carbon atoms.
6 . The composition according to claim 4 or 5 further comprising a saturated or unsaturated fatty acid having 10 to 22 carbon atoms.
7 . The composition according to claim 6 , wherein the saturated or unsaturated fatty acid having 3 to 22 carbon atoms is at least one selected from the group consisting of lactic acid, levulinic acid, decanoic acid, oleic acid, isostearic acid, and myristic acid.
8 . The composition according to claim 5 , wherein the alkanolamine is at least one selected from the group consisting of triethanolamine, triisopropanolamine, and diisopropanolamine.
9 . The composition according to claim 5 , wherein the fatty acid-based ionic liquid and/or the salicylic acid-based ionic liquid are at least one selected from the group consisting of triethanolamine lactate, triisopropanolamine lactate, triethanolamine levulinate, diisopropanolamine levulinate, triisopropanolamine decanoate, triethanolamine salicylate, diisopropanolamine oleate, triethanolamine isostearate, diisopropanolamine isostearate, and diisopropanolamine myristate.
10 . The composition according to any one of claims 1 to 9 , wherein the lipophilic plaster base material comprises an elastomeric styrene-isoprene-styrene block copolymer.
11 . The composition according to any one of claims 1 to 10 , wherein the drug is selected from a small molecular medicinal compound, a protein medicine, an antigen peptide, or a nucleic acid derivative.
12 . The composition according to any one of claims 1 to 11 , wherein the organic solvent is contained as shown in the following inequality:
the
amount
of
the
solvent
to
be
added
(
the
volume
of
the
solvent
to
be
added
)
<
the
amount
of
the
powder
to
be
added
the
tap
density
of
the
powder
(
the
volume
of
the
powder
to
be
added
)
×
1.2Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.